Novo Nordisk A/S Class B Profit Margin

As of the most recent data (March 2026), NONOF shows a profit margin of 37.21%. That compares with 34.51% in the prior-year period — up 7.8% year over year. That is above the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's profit margin is now 37.21% (was 34.51%) — a 7.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

The Healthcare sector average profit margin is about 15.58%. Novo Nordisk A/S Class B is at 37.21%, which is higher that average. That is roughly 138.7% above the sector mean. Use the comparison chart on this page to see how NONOF stacks up against individual peers as well.

That compares with 34.51% in the prior-year period — up 7.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Novo Nordisk A/S Class B with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 37.21%) with ownership activity and broader fundamentals.